Metabolic Bariatric Surgery Leads to Similar Benefits for Diabetes Management and Glycaemia in Remitters and Non-Remitters
In brief
Gastric bypass lowers adjusted HbA1c by about 39 mmol/mol in remitters and non-remitters
In a prospective cohort of 67 adults with type 2 diabetes, Roux-en-Y gastric bypass produced similar medication-adjusted HbA1c improvements in those who did and did not reach remission at 12 to 15 months. A separate audit of 195 patients confirmed the pattern. Even patients less likely to remit improved, so remission scores should not decide who is offered surgery.
- Journal
- Diabetes, obesity & metabolism (Q1)
- Published
- 10 November 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Julia S Kenkre, Sophie Jones, Wann Jia Loh, Iona Davies, Tina Mazaheri, Saleem Ansari, et al.
- PMID
- 43010194
- DOI
- 10.1111/dom.71522
Why clinicians should know about it
- Picked for Bariatric and Metabolic Surgery (paper of the day, 17 November 2026): RYGB diabetes outcomes challenge remission-based surgical selection
Abstract
AIMS: Metabolic bariatric surgery (MBS), for example, Roux-en-Y gastric bypass (RYGB) can lead to diabetes remission. However, this crude dichotomous outcome fails to fully capture post-operative improvements in glycaemia and reduced medication burden in people who do not remit. The objectives of this research were to investigate predictors of diabetes remission in a multiethnic cohort and to detail post-operative improvements in glycaemia and diabetes management. MATERIALS AND METHODS: Prospective observational study of a discovery cohort comprising 67 adults with obesity and Type 2 diabetes, undergoing a standardised RYGB in the United Kingdom or Singapore. Diabetes remission at 12-15 months was the primary outcome. An adjusted HbA1c was calculated using measured HbA1c and the doses/types of diabetes medications to estimate HbA1c without medication. Findings were validated by retrospective clinical audit of a separate UK cohort of 195 individuals undergoing RYGB. RESULTS: Diabetes remission was predicted by diabetes duration, measures of treatment intensity and resulting glycaemia (expressed as adjusted HbA1c) and post-prandial insulin secretion. Both remitters and non-remitters in the discovery cohort showed similar improvements in adjusted HbA1c (-38.2 ± 17.5 mmol/mol vs. -39.5 ± 15.5 mmol/mol, respectively, p = 0.739), a finding confirmed in the validation cohort. CONCLUSIONS: While those who do not experience post-MBS remission have a longer diabetes duration and higher baseline adjusted HbA1c, they benefit similarly from improvements in glycaemia and de-escalation of treatment as those who remit. We suggest that the likelihood of diabetes remission, as assessed by scoring systems, should not be used as a criterion to recommend MBS to patients.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.